Wilmington Healthcare launches new platform to map the formulary landscape
February 4, 2021 |
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
4 February 2021
Wilmington Healthcare launches new platform to map the formulary landscape
Healthcare intelligence provider Wilmington Healthcare has launched a new platform that enables pharma companies to develop a clear picture of formulary status across therapy areas and territories in the UK.
Known as InFormulary XD, the solution uses a unique blend of data and real-world evidence to provide an objective view of the status of a product by indication, on formularies and within guidelines.
Users can drill down into NHS localities within defined territories to gain a more detailed view of how their products are performing in primary and secondary care and better understand the challenges where formularies overlap.
The tool’s grading system also enables companies to clearly see where their brands sit on formularies and benchmark their performance against the competition using a wealth of data and insight.
In addition, the platform can be used to connect formulary information with other data sources, such as key stakeholder databases and NHS documents associated with product indication and target formularies.
Armed with data and insights from the platform, pharma can create compelling go-to-market plans to improve or maintain market position, monitor progress and keep abreast of formulary changes at a glance.
Gareth Thomas, Managing Director of Wilmington Healthcare, said: “The formulary landscape is not only multi-layered and complex, it is also changing quickly as the NHS adopts the integrated care models outlined in the Long-term Plan. This means that formulary data must be regularly reviewed and updated.
“Our new InFormulary XD enables customers to build and maintain a comprehensive view of a product’s formulary status in the UK in real-time and benchmark its performance against the competition. This level of insight, combined with related stakeholder data, gives companies a real competitive advantage in everything from strategic planning, budgeting and resourcing to customer targeting.”
Ends
Notes to Editors
For more information, please contact: Andrew Baud and Catherine McNulty, Tala, +44 (0) 20 3397 3383 or +44 (0) 7775 715775, Email: andrew.baud@teamtala.com /catherine.mcnulty@teamtala.com
This content was provided by Wilmington Healthcare
Company Details
Latest Content from Wilmington Healthcare
How will Sustainability and Transformation Plans (STPs) change the NHS commissioning landscape?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, take a look at new commissioning structures and what they mean for pharma
New report shows Traumatic Brain Injury (TBI) is a major threat to older people
A report by healthcare intelligence provider Wilmington Healthcare and the charity, United Kingdom Acquired Brain Injury Forum (UKABIF), shows that many hospital admissions in England for Traumatic Brain Injury (TBI)...
How will Sustainability and Transformation Plans (STPs) change the NHS in 2017?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess the impact that STPs will have on the NHS and what this means for pharma.
How can pharma help the NHS drive much-needed change in mental health services?
Laurence Mascarenhas, of Wilmington Healthcare, assesses how pharma can help the NHS to achieve Parity of Esteem (PoE) in mental health
How can the NHS deliver integrated care?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explain the changes needed to help the NHS provide a more holistic, joined up experience for patients
How can pharma engage with NHS Vanguards?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, explore the opportunities for pharma to help NHS vanguards develop new models of care.
What does the Five Year Forward View mean for pharma?
Sue Thomas and Paul Midgley, of Wilmington Healthcare, assess how the Five Year Forward View (5YFV) is changing the NHS and how pharma can get involved in redesigning NHS services.